Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction
IJC Heart & Vasculature, ISSN: 2352-9067, Vol: 9, Page: 55-62
2015
- 5Citations
- 38Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- CrossRef1
- Captures38
- Readers38
- 38
Review Description
Existing diagnostic guidelines for heart failure with preserved ejection fraction ( HFPEF ) primarily comprise natriuretic peptides and echocardiographic assessment, highlighting the role of diastolic dysfunction. However, recent discoveries of novel plasma markers implicated in pathophysiology of heart failure and technological advances in imaging provide additional biomarkers which are potentially applicable to HFPEF. The evidence base for plasma extra-cellular matrix (ECM) peptides, galectin-3, ST2, GDF-15 and pentraxin-3 is reviewed. Furthermore, the capabilities of novel imaging techniques to assess existing parameters (e.g. left ventricular ejection fraction, systolic & diastolic function, chamber size) and additional derangements of the ECM, myocardial mechanics and ischaemia evaluation are addressed.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2352906715300166; http://dx.doi.org/10.1016/j.ijcha.2015.07.004; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84942047256&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/28785707; https://linkinghub.elsevier.com/retrieve/pii/S2352906715300166
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know